Product Profiles: Non-Small Cell Lung Cancer - New Study Released

July 12, 2012 - PRLog -- The non-small cell lung cancer pipeline is growing as a result of an increased understanding of the disease's heterogeneity, which has led to the development of personalized therapies targeting distinct patient subtypes. The success of these personalized therapies is likely to incentivize pharmaceutical companies to continue developing targeted therapies for niche patient populations.

Report Scope

* Analysis of marketed NSCLC drugs - development history, key clinical trial data, and assessment of clinical and commercial attractiveness
* Analysis of marketed drugs in comparison to current standard of care
* In-depth analysis of late-stage pipeline drugs - development overview, SWOT analysis, and assessment of clinical and commercial attractiveness
* Discussion and assessment of pipeline drugs' ability to meet unmet needs in treatment of non-small cell lung cancer

Report Highlights

Pipeline drugs such as Bristol-Myers Squibb's Erbitux (cetuximab) and Roche's MetMab (onartuzumab) are currently being trialed in combination with platinum chemotherapy and Avastin respectively. Roche will inevitably benefit if MetMab is approved in this setting given Avastin's already established physician familiarity and high uptake.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/434400_product_profiles_nonsma...
------------------------------------------------------------

Targeted therapies maintain competition for greater market share. Avastin remains dominant, particularly in the US, but Tarceva (erlotinib), Iressa (gefitinib) and Xalkori (crizotinib) will increase pressure on Avastin given that their use in specific patient subsets avoids exposing unsuitable patients to unnecessary side-effects.

Targeted and immunotherapeutic drugs dominate the late-stage pipeline. Lucanix (belagenpumatucel-L) and Stimuvax (BLP-25) are the most advanced immunotherapies in the pipeline, looking set to enter the market in the second-line and maintenance settings respectively. No immunotherapies are currently approved for non-small cell lung cancer

Reasons to Get this Report

* Understand the dynamics of non-small cell lung cancer therapy and identify the market leaders in this competitive indication.
* Compare and assess current late-stage pipeline drugs according to market positioning, commercial potential and clinical efficacy.
* Understand how pipeline drugs will be used with current therapies and how the market is accessed through less competitive treatment settings.

Partial Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Strategic scoping and focus
* Datamonitor key findings
* Related reports

PRODUCT OVERVIEW

* Key marketed and pipeline drugs

MARKETED PRODUCT PROFILES: MOLECULAR TARGETED THERAPIES

* Avastin (bevacizumab; Roche/Genentech/Chugai)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness
* Biomarkers need to be validated if Avastin is to maintain its position
* Indication expansions in NSCLC a struggle

* Iressa (gefitinib; AstraZeneca)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Tarceva (erlotinib; Genentech/Roche/Chugai/OSI)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

* Xalkori (crizotinib; Pfizer)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Product positioning
* Clinical and commercial attractiveness

PIPELINE PRODUCT PROFILES: CYTOTOXICS

* Halaven (eribulin; Eisai)

* Drug overview
* Drug profile
* Development overview
* Demonstrated activity in taxane sensitive NSCLC
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

PIPELINE PRODUCT PROFILES: IMMUNOTHERAPIES

* GSK1572932A (astuprotimut-r; GlaxoSmithKline)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Lucanix (belagenpumatucel-L; NovaRx)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Stimuvax (BLP 25; Oncothyreon)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Talactoferrin (Agennix)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Yervoy (ipilimumab; Bristol Myers Squibb)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

PIPELINE PRODUCT PROFILES: MOLECULAR TARGETED THERAPIES

* Dacomitinib (PF-00299804; Pfizer)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Erbitux (cetuximab; Bristol-Myers Squibb)

* Drug overview
* Drug profile
* Development overview
* SWOT analysis
* Satisfaction of unmet needs
* Clinical and commercial attractiveness

* Ganetespib (STA-9090; Synta)

* Drug overview
*

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4344...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.